Tracleer helps PAH patients with scleroderma

	Tweet

Tracleer has shown positive long-term impact in treating pulmonary arterial hypertension (PAH) in patients with systemic sclerosis (scleroderma), the drug-maker Actelion said on Friday.

In abstracts presented at a European rheumatology conference, Actelion said that data showed that Tracleer, also known by its generic name bosentan, helped patients do better in physical performance tests over short and long periods.

"Over 12 or 16 weeks, patients treated with bosentan improved by 14.6 metres in the 6-minute walk test while patients in the placebo group deteriorated by 22.2 metres,” Actelion said.

The company said that as many as 15 percent of scleroderma patients develop PAH and the prognosis is extremely poor. Without treatment there is a median survival rate of just 12 months for scleroderma patients diagnosed with PAH, the Swiss biotech firm said.

RELATED STORIES:
Canada signals crackdown on Internet pharmacies   Two Abbott HIV drug ads misleading, FDA says   ‘Anti-ageing’ medicines on the way   Researchers Discover New Effect for Insulin   Vanderbilt Medical Experts Propose FDA Drug Approval Changes   Antidepressant Approved for Diabetes Pain   Roche in talks with WHO to stockpile Tamiflu   Risks of old, new diet drugs face U.S. scrutiny   Pfizer pulling ‘wild thing’ Viagra ads   FDA approves generic version of Effexor (venlafaxine)   Roswell Park research aids development of myeloma drug   FDA warns Chiron over flu vaccine plant

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]